SpringLeaf Therapeutics Seals $15M
SpringLeaf Therapeutics has closed $15 million in a Series B financing led by new investor SR One, the venture capital arm of GlaxoSmithKline, with participation from existing shareholders Flybridge Capital Partners and North Bridge Venture Partners. SR One partner Brian Gallagher will join SpringLeaf’s board as a result. SpringLeaf is based in Boston.
12 May 2011•3 mins read
